Tag Archive for: complement system

Commit Biologics appoints serial biotech founder as new CEO to take complement-powered immune engagers into the clinic

/in

Dr. Thomas L. F. Montgomery Andresen joins from T-Cypher Bio Follows breakthrough non-human primate data demonstrating deep B-cell depletion without cytokine release Commit is poised to nominate its first two clinical development candidates later in 2026 COPENHAGEN, Denmark — March 11, 2026 — Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed […]

Read more

Commit Biologics achieves proof-of-concept for novel Complement Engager platform in non-human primates  

/in

Novel approach harnessing the power of the complement system to drive potent cell depletion Single-dose study shows rapid and sustained immune cell depletion in blood and tissues with a very favourable safety profile Commit Biologics’ CEO Mikkel Wandahl Pedersen to present data at PEGS Europe summit, November 11-13, 2025 in Lisbon, Portugal Aarhus, Denmark, November […]

Read more

Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board

/in

Industry and scientific experts in molecular biology, immunology and antibody research appointed to help develop Commit’s BiCE™ technology platform to treat autoimmune disease and cancer Leading antibody expert Janine Schuurman to co-chair Commit’s Scientific Advisory Board alongside Commit’s CEO Mikkel Wandahl Pedersen Joined by Paul Parren, Gavin Thurston, Susan Kalled, and Esper Boel on the […]

Read more

Commit Biologics appoints Mikkel Wandahl Pedersen as Chief Scientific Officer

/in

Highly experienced leader with demonstrated track record of antibody-based drug discovery and pipeline advancement Strengthens Commit’s leadership team after emerging from stealth with €16m seed financing Dr Pedersen will spearhead research and development of Commit’s BiCETM technology as the Company moves towards drug candidate (DC) nomination Aarhus, Denmark, 15 October 2024 – Commit Biologics (“Commit”), […]

Read more

Commit Biologics to present data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement Therapeutics

/in

Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Poster to be presented on Commit’s Bispecific Complement Engaging (BiCE™) platform   Aarhus, Denmark, 10 June 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer […]

Read more